Form 4: Longeveron Chief Medical Officer Discloses Future Share Withholding for Tax Obligations

Longeveron Inc.'s Chief Medical Officer, Nataliya Agafonova, reported a future disposition of 7,431 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit award vesting, effective July 1, 2025.

Summary

• Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., filed a Form 4 disclosing a transaction involving the company's Class A Common Stock.
• On July 1, 2025, 7,431 shares of Class A Common Stock are scheduled to be disposed of at a price of $1.28 per share.
• This disposition is specifically for shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this reported transaction, Nataliya Agafonova will beneficially own 136,697 shares of Class A Common Stock, which includes RSUs subject to future vesting.

Sentiment

Score: 5

Explanation: The transaction is a routine administrative event (shares withheld for tax on RSU vesting) and is generally neutral in its implications for the company's operations or financial health.

Positives

• The transaction is a standard procedure for covering tax liabilities on RSU vesting, indicating the vesting of equity compensation for an executive.
• The transaction is part of a pre-planned Rule 10b5-1(c) plan, which can reduce concerns about opportunistic insider trading.

Negatives

• The transaction represents a reduction in the direct shareholding of the Chief Medical Officer, though it is for tax purposes rather than a discretionary sale.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent market risks associated with holding company stock.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a disclosure of a future, pre-planned transaction.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction related to equity compensation and does not provide broader industry context or trends. It reflects standard compensation practices within publicly traded companies, including those in the biotechnology or healthcare sector where Longeveron operates.

Comparison to Industry Standards

• This Form 4 filing details a standard equity compensation event (RSU vesting and tax withholding) common across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• It does not provide financial results or operational metrics that would allow for a direct comparison to specific comparable companies' performance or projects, such as R&D spending or clinical trial outcomes of companies like Moderna, Pfizer, or BioNTech.
• The share price of $1.28 is specific to LGVN at the time of the reported transaction.

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The transaction involves an officer of the company and is related to her equity compensation, which is a common type of related party transaction. No unusual or new related party dealings are disclosed beyond the standard equity compensation.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in shares held by an executive, but it is a routine event for tax purposes and is not typically considered a discretionary sale. The shares were already part of the compensation plan.
• Employees: The RSU vesting indicates standard equity compensation practices for executives within the company.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing, as it reports a pre-planned transaction.

Key Dates

Keywords

Longeveron Inc., LGVN, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Officer Compensation, Nataliya Agafonova, Chief Medical Officer, Rule 10b5-1 Plan